Marktanalyse - Hyperglycemia - Pipeline Review, H2 2016

Global Markets Direct
12.2016
44 Seiten

 
Typ:
Marktanalyse
Verfüg­barkeit:
verfügbar
Regionen/­Länder:
  • Europa
  • Asien / Pazifik
  • Mittlerer Osten / Afrika
  • Nordamerika / USA
  • Australien
  • Mittel- / Südamerika
Sprache:
Englisch

Bitte wählen Sie ein Lieferformat und klicken Sie unten auf einen Bestellbutton:

PDF-Datei per E-Mail, Single User Price, versandkostenfrei
PDF-Datei per E-Mail, Site License Price**, versandkostenfrei
PDF-Datei per E-Mail, Enterprisewide Price (Global Site License)***, versandkostenfrei


Hinweise: **The report can be shared by users within one office (one geographical location) ***Across Geographical locations (by the purchasing company only)

Hyperglycemia - Pipeline Review, H2 2016


Summary


Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Hyperglycemia — Pipeline Review, H2 2016, provides an overview of the Hyperglycemia (Metabolic Disorders) pipeline landscape.

Hyperglycemia is a condition that occurs when blood glucose levels get too high. Several factors can contribute to hyperglycemia, including food and physical activity choices, illness, non-diabetes medications, or not taking enough glucose-lowering medication. Symptoms include frequent urination, blurred vision, fatigue headache, nausea and vomiting, dry mouth, coma and confusion. Treatment includes anti-hyperglycemic therapy and insulin therapy.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Hyperglycemia — Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Hyperglycemia (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Hyperglycemia (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Hyperglycemia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase I and Preclinical stages are 1 and 4 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 6 and 1 molecules, respectively.Hyperglycemia.

Hyperglycemia (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.


Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Hyperglycemia (Metabolic Disorders).
- The pipeline guide reviews pipeline therapeutics for Hyperglycemia (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Hyperglycemia (Metabolic Disorders) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Hyperglycemia (Metabolic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Hyperglycemia (Metabolic Disorders)


Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Hyperglycemia (Metabolic Disorders).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Hyperglycemia (Metabolic Disorders) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 4

Introduction 5

Global Markets Direct Report Coverage 5

Hyperglycemia Overview 6

Therapeutics Development 7

Pipeline Products for Hyperglycemia - Overview 7

Pipeline Products for Hyperglycemia - Comparative Analysis 8

Hyperglycemia - Therapeutics under Development by Companies 9

Hyperglycemia - Therapeutics under Investigation by Universities/Institutes 10

Hyperglycemia - Pipeline Products Glance 11

Clinical Stage Products 11

Early Stage Products 12

Hyperglycemia - Products under Development by Companies 13

Hyperglycemia - Products under Investigation by Universities/Institutes 14

Hyperglycemia - Companies Involved in Therapeutics Development 15

Eli Lilly and Company 15

Kissei Pharmaceutical Co Ltd 16

Mitsubishi Tanabe Pharma Corp 17

PhaseBio Pharmaceuticals Inc 18

Hyperglycemia - Therapeutics Assessment 19

Assessment by Monotherapy Products 19

Assessment by Target 20

Assessment by Mechanism of Action 22

Assessment by Route of Administration 24

Assessment by Molecule Type 26

Drug Profiles 28

CDR-267F018 - Drug Profile 28

Product Description 28

Mechanism Of Action 28

R&D Progress 28

Drugs to Inhibit ABHD6 for Gastrointestinal and Metabolic Disorders - Drug Profile 29

Product Description 29

Mechanism Of Action 29

R&D Progress 29

FGH-10019 - Drug Profile 30

Product Description 30

Mechanism Of Action 30

R&D Progress 30

KR-62980 - Drug Profile 31

Product Description 31

Mechanism Of Action 31

R&D Progress 31

PE-0139 - Drug Profile 33

Product Description 33

Mechanism Of Action 33

R&D Progress 33

Recombinant Peptide to Agonize Glucagon Receptor for Hyperglycemia - Drug Profile 35

Product Description 35

Mechanism Of Action 35

R&D Progress 35

Small Molecule to Inhibit SGLT1 for Postprandial Hyperglycemia - Drug Profile 36

Product Description 36

Mechanism Of Action 36

R&D Progress 36

Small Molecules to Antagonize PST Receptor for Dysglycemic States - Drug Profile 37

Product Description 37

Mechanism Of Action 37

R&D Progress 37

Small Molecules to Inhibit DPP-IV for Hyperglycemia - Drug Profile 38

Product Description 38

Mechanism Of Action 38

R&D Progress 38

Small Molecules to Inhibit PEPCK for Type 2 Diabetes and Hyperglycemia - Drug Profile 39

Product Description 39

Mechanism Of Action 39

R&D Progress 39

Small Molecules to Inhibit Prokineticin Receptor for Metabolic Disorders - Drug Profile 40

Product Description 40

Mechanism Of Action 40

R&D Progress 40

Synthetic Peptides to Antagonize Glucagon Receptor for Hyperglycemia and Type 2 Diabetes - Drug Profile 41

Product Description 41

Mechanism Of Action 41

R&D Progress 41

Hyperglycemia - Dormant Projects 42

Appendix 43

Methodology 43

Coverage 43

Secondary Research 43

Primary Research 43

Expert Panel Validation 43

Contact Us 43

Disclaimer 44





List of Tables

Number of Products under Development for Hyperglycemia, H2 2016 7

Number of Products under Development for Hyperglycemia - Comparative Analysis, H2 2016 8

Number of Products under Development by Companies, H2 2016 9

Number of Products under Investigation by Universities/Institutes, H2 2016 10

Comparative Analysis by Clinical Stage Development, H2 2016 11

Comparative Analysis by Early Stage Development, H2 2016 12

Products under Development by Companies, H2 2016 13

Products under Investigation by Universities/Institutes, H2 2016 14

Hyperglycemia - Pipeline by Eli Lilly and Company, H2 2016 15

Hyperglycemia - Pipeline by Kissei Pharmaceutical Co Ltd, H2 2016 16

Hyperglycemia - Pipeline by Mitsubishi Tanabe Pharma Corp, H2 2016 17

Hyperglycemia - Pipeline by PhaseBio Pharmaceuticals Inc, H2 2016 18

Assessment by Monotherapy Products, H2 2016 19

Number of Products by Stage and Target, H2 2016 21

Number of Products by Stage and Mechanism of Action, H2 2016 23

Number of Products by Stage and Route of Administration, H2 2016 25

Number of Products by Stage and Molecule Type, H2 2016 27

Hyperglycemia - Dormant Projects, H2 2016 42





List of Figures

Number of Products under Development for Hyperglycemia, H2 2016 7

Number of Products under Development for Hyperglycemia - Comparative Analysis, H2 2016 8

Number of Products under Development by Companies, H2 2016 9

Number of Products under Investigation by Universities/Institutes, H2 2016 10

Comparative Analysis by Early Stage Products, H2 2016 12

Assessment by Monotherapy Products, H2 2016 19

Number of Products by Targets, H2 2016 20

Number of Products by Stage and Targets, H2 2016 20

Number of Products by Mechanism of Actions, H2 2016 22

Number of Products by Stage and Mechanism of Actions, H2 2016 22

Number of Products by Routes of Administration, H2 2016 24

Number of Products by Stage and Routes of Administration, H2 2016 24

Number of Products by Molecule Types, H2 2016 26

Number of Products by Stage and Molecule Types, H2 2016 26

* Alle Preise sind netto ausgewiesen. In Abhängigkeit von Ihrer Rechnungsanschrift ist hierauf noch USt. zu entrichten (Deutschland z.Z. 19%). Unser Angebot richtet sich ausschließlich an Unternehmen, Gewerbetreibende und Freiberufler.

 

Über marktforschung.de

Branchenwissen an zentraler Stelle bündeln und abrufbar machen – das ist das Hauptanliegen von marktforschung.de. Unser breites Informationsangebot rund um die Marktforschung richtet sich sowohl an Marktforschungsinstitute, Felddienstleister, Panelbetreiber und Herausgeber von Studien, Marktdaten sowie Marktanalysen als auch an deren Kunden aus Industrie, Handel und Dienstleistungsgewerbe.

facebook twitter google plus